Reviva Pharmaceuticals Holdings, Inc. (RVPH)
OTCMKTS · Delayed Price · Currency is USD
0.3521
0.00 (0.00%)
At close: May 14, 2026
Reviva Pharmaceuticals Holdings Employees
Reviva Pharmaceuticals Holdings had 14 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
14
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,187,718
Market Cap
4.51M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 14 | 0 | - |
| Dec 31, 2024 | 14 | -1 | -6.67% |
| Dec 31, 2023 | 15 | 5 | 50.00% |
| Dec 31, 2022 | 10 | 5 | 100.00% |
| Dec 31, 2021 | 5 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Adaptimmune Therapeutics | 506 |
| CASI Pharmaceuticals | 233 |
| Vaccinex | 27 |
| Iterum Therapeutics | 9 |
| Mosaic ImmunoEngineering | 7 |
| AccuStem Sciences | 4 |
| Bioxytran | 2 |
Reviva Pharmaceuticals Holdings News
- 1 day ago - Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 6 weeks ago - Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering - GlobeNewsWire
- 2 months ago - Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering - GlobeNewsWire
- 4 months ago - Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum - GlobeNewsWire
- 5 months ago - Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia - GlobeNewsWire
- 6 months ago - Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 7 months ago - Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025 - GlobeNewsWire